Expression of the costimulatory molecule CD86, but not CD80, in keratinocytes of normal cervical epithelium and human papillomavirus-16 positive low squamous intraepithelial lesions

International Journal of Gynecological Cancer

Volumn 17, Issue 3, 2007, Pages 571-580

  Ortiz Sanchez E ^a   Chavez Olmos P ^a   Pina Sanchez P ^b   Salcedo, M ^b   Garrido, E ^a  

^a DEPARTAMENTO DE FÍSICA   (Mexico)

^b HOSPITAL DE ONCOLOGÍA   (Mexico)

Author keywords

CD86; Cervical cancer; Costimulatory molecule; LSIL

Indexed keywords

B7 ANTIGEN; CD86 ANTIGEN; CYTOKINE; INTERLEUKIN 10; MESSENGER RNA;

ARTICLE; CELL ACTIVATION; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DOWN REGULATION; FEMALE; HUMAN; HUMAN CELL; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN TISSUE; IMMUNOSURVEILLANCE; IN SITU HYBRIDIZATION; KERATINOCYTE; LOW SQUAMOUS INTRAEPITHELIAL LESION; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN EXPRESSION; UTERINE CERVIX CANCER; UTERINE CERVIX DISEASE; UTERINE CERVIX EPITHELIUM; VERRUCA VULGARIS;

ANTIGENS, CD80; ANTIGENS, CD86; CERVICAL INTRAEPITHELIAL NEOPLASIA; CERVIX UTERI; EPITHELIUM; FEMALE; HUMAN PAPILLOMAVIRUS 16; HUMANS; INTERLEUKIN-10; KERATINOCYTES; NEOPLASMS, SQUAMOUS CELL; UTERINE CERVICAL NEOPLASMS;

EID: 34248333739     PISSN: 1048891X     EISSN: 15251438     Source Type: Journal    
DOI: 10.1111/j.1525-1438.2007.00904.x     Document Type: Article

References (63)

1. Burk RD, Ho GY, Beardsley L, Lempa M, Peters M, Bierman R. Sexual behavior and partner characteristics are the predominant risk factors for genital human papillomavirus infection in young women. J Infect Dis 1996 174:679 89.
2. Evander M, Edlund K, Gustafsson A et al. Human papillomavirus infection is transient in young women: a population-based cohort study. J Infect Dis 1995 171:1026 30.
3. Koutsky L. Epidemiology of genital human papillomavirus infection. Am J Med 1997 102:3 8.
4. Duggan MA, McGregor SE, Stuart GC et al. The natural history of CIN I lesions. Eur J Gynaecol Oncol 1998 19:338 44.
5. Ho GY, Bierman R, Beardsley L, Chang CJ, Burk RD. Natural history of cervicovaginal papillomavirus infection in young women. N Engl J Med 1998 338:423 8.
6. Charleson FC, Norval M, Benton EC, Hunter JA. Lymphoproliferative responses to human papillomaviruses in patients with cutaneous warts. Br J Dermatol 1992 127:551 9.
7. Serraino D, Carrieri P, Pradier C et al. Risk of invasive cervical cancer among women with, or at risk for, HIV infection. Int J Cancer 1999 82:334 7.
8. Palefsky JM, Minkoff H, Kalish LA et al. Cervicovaginal human papillomavirus infection in human immunodeficiency virus-1 (HIV)-positive and high-risk HIV-negative women. J Natl Cancer Inst 1999 91:226 36.
9. Ellerbrock TV, Chiasson MA, Bush TJ et al. Incidence of cervical squamous intraepithelial lesions in HIV-infected women. JAMA 2000 283:1031 47.
10. Giannini SL, Hubert P, Doyen J, Boniver J, Delvenne P. Influence of the mucosal epithelium microenvironment on Langerhans cells: implications for the development of squamous intraepithelial lesions of the cervix. Int J Cancer 2002 97:654 9.
11. Chen LP, Thomas EK, Hu SL, Hellstrom I, Hellstrom KE. Human papillomavirus type 16 nucleoprotein E7 is a tumor rejection antigen. Proc Natl Acad Sci 1991 88:110 4.
12. Feltkamp MC, Smits HL, Vierboom MP et al. Vaccination with cytotoxic T lymphocyte epitope-containing peptide protects against a tumor induced by human papillomavirus type 16-transformed cells. Eur J Immunol 1993 23:2242 9.
13. De Bruijn ML, Schuurhuis DH, Vierboom MP et al. Immunization with human papillomavirus type 16 (HPV16) oncoprotein-loaded dendritic cells as well as protein in adjuvant induces MHC class I-restricted protection to HPV16-induced tumor cells. Cancer Res 1998 58:24 31.
14. Ressing ME, Offringa R, Toes RE et al. Immunotherapy of cancer by peptide-based vaccines for the induction of tumor-specific T cell immunity. Immunotechnology 1996 2:241 51.
15. Bontkes HJ, de Gruijl TD, van den Muysenberg AJ et al. Human papillomavirus type 16 E6/E7-specific cytotoxic T lymphocytes in women with cervical neoplasia. Int J Cancer 2000 88:92 8.
16. Alexander M, Salgaller ML, Celis E et al. Generation of tumor-specific cytolytic T lymphocytes from peripheral blood of cervical cancer patients by in vitro stimulation with a synthetic human papillomavirus type 16 E7 epitope. Am J Obstet Gynecol 1996 175:1586 93.
17. Evans EM, Man S, Evans AS, Borysiewicz LK. Infiltration of cervical cancer tissue with human papillomavirus-specific cytotoxic T-lymphocytes. Cancer Res 1997 57:2943 50.
18. Steller MA, Gurski KJ, Murakami M et al. Cell-mediated immunological responses in cervical and vaginal cancer patients immunized with a lipidated epitope of human papillomavirus type 16 E7. Clin Cancer Res 1998 4:2103 9.
19. Daftarian P, Mansour M, Benoit AC et al. Eradication of established HPV 16-expressing tumors by a single administration of a vaccine composed of a liposome-encapsulated CTL-T helper fusion peptide in a water-in-oil emulsion. Vaccine 2006 24:5235 44.
20. Hilders CG, Ras L, van Eendenburg JD, Nooyen Y, Fleuren GJ. Isolation and characterization of tumor-infiltrating lymphocytes from cervical carcinoma. Int J Cancer 1994 57:805 13.
21. Jenkins MK, Pardoll DM, Mizuguchi J, Quill H, Schwartz RH. T-cell unresponsiveness in vivo and in vitro: fine specificity of induction and molecular characterization of the unresponsive state. Immunol Rev 1987 95:113 35.
22. Liwski RS, Chase JC, Baldridge WH, Sadek I, Rowden G, West KA. Prolonged costimulation is required for naive T cell activation. Immunol Lett 2006 108:135 43.
23. Magistrelli G, Caron G, Gauchat JF, Jeannin P, Bonnefoy JY, Delneste Y. Identification of an alternatively spliced variant of human CD86 mRNA. Biochem Biophys Res Commun 2001 280:1211 5.
24. Nickoloff BJ, Turka LA. Immunological functions of non-professional antigen-presenting cells: new insights from studies of T-cell interactions with keratinocytes. Immunol Today 1994 15:464 9.
25. Mota F, Rayment N, Chong S, Singer A, Chain B. The antigen-presenting environment in normal and human papillomavirus (HPV)-related premalignant cervical epithelium. Clin Exp Immunol 1999 116:33 40.
26. Bernsen MR, Hakansson L, Gustafsson B et al. On the biological relevance of MHC class II and B7 expression by tumour cells in melanoma metastases. Br J Cancer 2003 88:424 31.
27. Knörr C, Amrehn CH, Seeberger H et al. Expression of costimulatory molecules in low-grade mucosa-associated lymphoid tissue-type lymphomas in vivo. Am J Pathol 1999 155:2019 25.
28. Maeda A, Yamamoto K, Yamashita K et al. The expression of co-stimulatory molecules and their relationship to the prognosis of human acute myeloid leukaemia: poor prognosis of B7-2-positive leukaemia. Br J Haematol 1998 102:1257 62.
29. Fujiwara K, Higashi T, Nouso K et al. Decreased expression of B7 costimulatory molecules and major histocompatibility complex class-I in human hepatocellular carcinoma. J Gastroenterol Hepathol 2004 19:1121 7.
30. So T, Takenoyama M, Ichiki Y et al. A different pattern of cytotoxic T lymphocyte recognition against primary and metastatic tumor cells in a patient with nonsmall cell lung carcinoma. Cancer 2005 103:200 8.
31. Thompson RH, Gillett MD, Cheville JC et al. Costimulatory B7-H1 in renal cell carcinoma patients: indicator of tumor aggressiveness and potential therapeutic target. Proc Natl Acad Sci 2004 101:17174 9.
32. Tirapu I, Huarte E, Guiducci C et al. Low surface expression of B7-1 (CD80) is an immunoescape mechanism of colon carcinoma. Cancer Res 2006 66:2442 50.
33. Villarroel-Dorrego M, Speight PM, Barrett AW. Expression of major histocompatibility complex class II and costimulatory molecules in oral carcinomas in vitro. Med Oral Patol Oral Cir Bucal 2005 10:188 95.
34. Wolfram RM, Budinsky AC, Brodowicz T et al. Defective antigen presentation resulting from impaired expression of costimulatory molecules in breast cancer. Int J Cancer 2000 88:239 44.
35. Suzuki M, Shinohara F, Sato K, Taniguchi T, Takada T, Rikiishi H. Interleukin-1β converting enzyme subfamily inhibitors prevent induction of CD86 molecules by butyrate through a CREB-dependent mechanism in HL60 cells. Immunol 2003 108:375 83.
36. Hidalgo A, Piña P, Guerrero G, Salcedo M. A simple method for the construction of small format tissue array. J Clin Pathol 2006 56:144 6.
37. Resnick RM, Cornelissen MT, Wright DK et al. Detection and typing of human papillomavirus in archival cervical cancer specimens by DNA amplification with consensus primers. J Natl Cancer Inst 1990 82:1477 84.
38. Shimada M, Fukushima M, Mukai H, Kato I, Nishikawa A, Fujinaga K. Amplification and specific detection of transforming gene region of human papillomavirus 16, 18, and 33 in cervical carcinoma by means of the polymerase chain reaction. Jpn J Cancer Res 1990 81:1 5.
39. Tatsumi T, Takehara T, Katayama K et al. Expression of costimulatory molecules B7-1 (CD80) and B7-2 (CD86) on human hepatocellular carcinoma. Hepathol 1997 25:1108 14.
40. Hsu EM, McNicol PJ, Guijon FB, Paraskevas M. Quantification of HPV-16 E6-E7 transcription in cervical intraepithelial neoplasia by reverse transcriptase polymerase chain reaction. Int J Cancer 1993 55:397 401.
41. Yang H, Wanner I, Roper SD, Chaudhari N. An optimized method for in situ hybridization with signal amplification that allows the detection of rare mRNAs. J Histochem Cytochem 1999 47:431 45.
42. Takagi A, Nishiyama C, Kanada S et al. Prolonged MHC class II expression and CIITA transcription in human keratinocytes. Biochem Biophys Res Commun 2006 347:388 93.
43. Sikorski M, Bobek M, Zrubek H, Marcinkiewicz J. Dynamics of selected MHC class I and II molecule expression in the course of HPV positive CIN treatment with the use of human recombinant IFN-gamma. Acta Obstet Gynecol Scand 2004 83:299 307.
44. Guimarães MA, Donadi EA. Immune cellular response to HPV: current concepts. Braz J Infect Dis 2004 8:1 9.
45. Lenschow DJ, Sperling AI, Cooke MP et al. Differential up-regulation of the B7-1 and B7-2 costimulatory molecules after Ig receptor engagement by antigen. J Immunol 1994 153:1990 7.
46. Symington FW, Brady W, Linsley PS. Expression and function of B7 on human epidermal Langerhans cells. J Immunol 1993 150:1286 95.
47. Salgado CG, Nakamura K, Sugaya M et al. Differential effects of cytokines and immunosuppressive drugs on CD40, B7-1, and B7-2 expression on purified epidermal Langerhans cells. J Invest Dermatol 1999 113:1021 7.
48. Chang CH, Furue M, Tamaki K. B7-1 expression of Langerhans cells is up-regulated by proinflammatory cytokines, and is down-regulated by interferon-gamma or by interleukin-10. Eur J Immunol 1995 25:394 8.
49. Wang SS, Hildesheim A. Viral and host factors in human papillomavirus persistence and progression. J Natl Cancer Inst Monographs 2003 31:35 40.
50. Frazer I. Prevention of cervical cancer through papillomavirus vaccination. Nat Rev Immunol 2004 4:48 54.
51. Kabsch K, Mossadegh N, Kohl A et al. The HPV-16 E5 protein inhibits TRAIL- and FasL-mediated apoptosis in human keratinocyte raft cultures. Intervirology 2004 47:48 56.
52. Ashrafi GH, Tsirimonaki E, Marchetti B et al. Down-regulation of MHC class I by bovine papillomavirus E5 oncoproteins. Oncogene 2002 21:248 59.
53. Ashrafi GH, Haghshenas MR, Marchetti B, O'Brien PM, Campo MS. E5 protein of human papillomavirus type 16 selectively downregulates surface HLA class I. Int J Cancer 2005 113:276 83.
54. de Gruijl TD, Bontkes HJ, Walboomers JM et al. Differential T helper cell responses to human papillomavirus type 16 E7 related to viral clearance or persistence in patients with cervical neoplasia: a longitudinal study. Cancer Res 1998 58:1700 6.
55. El-Sherif A, Seth R, Tighe P, Jenkins D. Quantitative analysis of IL-10 and IFN-γ mRNA levels in normal cervix and human papillomavirus type 16 associated cervical precancer. J Pathol 2001 195:179 85.
56. Hidalgo A, Baudis M, Petersen I et al. Microarray comparative genomic hybridization detection of chromosomal imbalances in uterine cervix carcinoma. BMC Cancer 2005 5:77.
57. Ronco LV, Karpova AY, Vidal M, Howley PM. Human papillomavirus 16 E6 oncoprotein binds to interferon regulatory factor-3 and inhibits its transcriptional activity. Genes Dev 1998 12:2061 72.
58. Park J, Kim EJ, Kwon HJ, Hwang ES, Mankoong SE, Um SJ. Inactivation of interferon regulatory factor-1 tumor suppressor protein by HPV E7 oncoprotein. J Biolumin Chemilumin 2000 275:6764 9.
59. Woodworth C, Simpson S. Comparative lymphokine secretion by cultured normal human cervical keratinocytes, papillomavirus-immortalized, and carcinoma cell lines. Am J Pathol 1993 142:1544 55.
60. Kim J, Modlin RL, Moy RL et al. IL-10 production in cutaneous basal and squamous cell carcinomas. A mechanism for evading the local T cell immune response. J Immunol 1995 155:2240 7.
61. Wei R, Jonakait GM. Neurotrophins and the anti-inflammatory agents interleukin-4 (IL-4), IL-10, IL-11 and transforming growth factor-beta1 (TGF-beta1) down-regulate T cell costimulatory molecules B7 and CD40 on cultured rat microglia. J Neuroimmunol 1999 95:8 18.
62. Pechhold K, Patterson NB, Craighead N, Lee KP, June CH, Harlan DM. Inflammatory cytokines IFN-gamma plus TNF-alpha induce regulated expression of CD80 (B7-1) but not CD86 (B7-2) on murine fibroblasts. J Immunol 1997 158:4921 9.
63. Marckmann S, Wiesemann E, Hilse R, Trebst C, Stangel M, Windhagen A. Interferon-beta up-regulates the expression of co-stimulatory molecules CD80, CD86, and CD40 on monocytes: significance for treatment of multiple sclerosis. Clin Exp Immunol 2004 138:499 506.